0000920465-20-000032.txt : 20200219 0000920465-20-000032.hdr.sgml : 20200219 20200219164745 ACCESSION NUMBER: 0000920465-20-000032 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200214 FILED AS OF DATE: 20200219 DATE AS OF CHANGE: 20200219 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rolke James CENTRAL INDEX KEY: 0001693858 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36282 FILM NUMBER: 20630576 MAIL ADDRESS: STREET 1: 10182 TELESIS COURT, 6TH FLOOR CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LA JOLLA PHARMACEUTICAL CO CENTRAL INDEX KEY: 0000920465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330361285 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4550 TOWNE CENTRE COURT CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-207-4264 MAIL ADDRESS: STREET 1: 4550 TOWNE CENTRE COURT CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 wf-form4_158214884842276.xml FORM 4 X0306 4 2020-02-14 0 0000920465 LA JOLLA PHARMACEUTICAL CO LJPC 0001693858 Rolke James C/O LA JOLLA PHARMACEUTICAL COMPANY, 4550 TOWNE CENTRE COURT SAN DIEGO CA 92121 0 1 0 0 Chief Scientific Officer Common Stock 2020-02-14 4 A 0 115 7.14 A 80535 D Stock Option (Right to Buy) 8.4 2020-02-14 4 A 0 115 0 A 2030-02-14 Common Stock 115.0 115 D These shares were acquired on 02/14/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. /s/ Ryan Murr, as attorney-in-fact for James Rolke 2020-02-19